Business
Pre-IPO Investment into Psych Capital
Pre-IPO Investment into Psych Capital.
About this update from Oscillate Plc
[{"type":"text","content":"\n \n THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS AMENDED (\"MAR\"). ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE (\"RIS\"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n 20 August 2021\n \n Oscillate plc\n \n \n AQSE: MUSH\n \n (“Company” or “Oscillate”)\n Oscillate completes Pre-IPO Investment into Psych Capital Limited\n Highlights\n \n Following recent re-positioning and re-structuring, Oscillate announces its first major investment into the emerging psychedelic science and healthcare industry;\n 10.4% pre-IPO stake acquired in Psych Capital Limited, a company on course to become one of the first UK quoted psychedelic entities;\n First step in ambitious plan to position Oscillate as a major strategic force in the European psychedelic marketplace.\n \n The Company is pleased to announce that it has acquired 30,000,000 ordinary shares in Psych Capital Limited, representing approximately 10.4% of the current issued share capital for a consideration of £300,000. Psych Capital is currently well advanced in its application process to be admitted to a UK regulated market, and expects to complete its IPO process shortly.\n Background to Psych Capital:\n Psych Capital was created by a group of professionals that are focused on disruptive healthcare solutions that are rapidly becoming accepted in developed communities, and this includes the recent rush to legalise the use of medicinal cannabis as the world begins to absorb and educate the true benefits of alternative drug application and interpretation.\n Psych Capital is focused on leveraging its experienced team that were early innovators in the medicinal & recreational cannabis industry and have developed a global network to replicate their success in the burgeoning medical psychedelic sector.\n The company is focused on identifying, funding and building future British and European leaders across psychedelic science and healthcare.\n To date Psych Capital has successfully advanced its business plan via, inter-alia,\n \n The creation of a global audience through its PSYCH data and content platform that covers 80 countries, worldwide, reaching over 30,000 users ranging from invest...